Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

2C-D: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Unity
Added dangerous interactions.
>Unity
Restyle intro. Remove 'History and culture' stub. Expand effects section and add descriptions. Grammatics.
Line 2: Line 2:
{{SubstanceBox/2C-D}}
{{SubstanceBox/2C-D}}


'''2,5-Dimethoxy-4-methylphenethylamine''' (also known as '''2C-M''' and more commonly as '''2C-D''') is a synthetic [[Psychoactive class::psychedelic]] of the [[Chemical class::phenethylamine]] chemical class that produces short-lived [[psychedelic]] effects comparable to those produced by [[mescaline]] and other [[2C-x]] compounds when [[routes of administration|administered]]. Its synthesis was first published in 1970 by a team from the Texas Research Institute of Mental Sciences.<ref>Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084</ref> Initial trials by [[Alexander Shulgin]] at sub-threshold doses in humans were carried out in 1964.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf</ref>
'''2,5-Dimethoxy-4-methylphenethylamine''' (also known as '''2C-M''' and more commonly as '''2C-D''') is a synthetic [[Psychoactive class::psychedelic]] of the [[Chemical class::phenethylamine]] chemical class that produces short-lived [[psychedelic]] effects when [[routes of administration|administered]]. Its sensory and cognitive effects profile has been described as being the most similar to that of [[mescaline]] among members of the [[2C-x family]], albeit with a notably shorter duration.


In his book [[PiHKAL]] ("Phenethylamines I Have Known And Loved"), Shulgin lists the dosage range as being from 20 to 60 mg. This is now regarded by many as a conservative estimate as it has since been reported that substantially higher doses can be taken to induce a full spectrum of classical psychedelic effects while remaining physically benign, a relatively unique quality in the [[2C-x family]].  
The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences.<ref>Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084</ref> Initial trials by [[Alexander Shulgin]] at sub-threshold doses in humans were carried out in 1964.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf</ref>
 
In his book [[PiHKAL]] ("Phenethylamines I Have Known And Loved"), Shulgin lists the dosage range as being from 20 to 60 mg. This is now regarded by some as a conservative estimate as it has since been reported that substantially higher doses are capable of inducing a full spectrum of classical psychedelic effects while remaining physically unthreatening, a relatively unique quality in the [[2C-x family]].
 
Many anecdotal reports suggest that it is calmer, easier to handle and more comfortable on the body than other closely related [[psychedelic]] [[phenethylamines]]. While not especially visual or physically euphoric, it is said to be very lucid in its head-space, analytical and cognitively unimpaired.


Lower doses of 2C-D (generally 10 mg or less) have been explored for its use as a potential [[nootropic]], albeit with mixed results.<ref>Lemaire, D. (1990). Erowid 2C-D Vault: Smart Pills, by Hosten & Lazar. Retrieved from https://www.erowid.org/chemicals/2cd/2cd_smartpills1.shtml</ref>
Lower doses of 2C-D (generally 10 mg or less) have been explored for its use as a potential [[nootropic]], albeit with mixed results.<ref>Lemaire, D. (1990). Erowid 2C-D Vault: Smart Pills, by Hosten & Lazar. Retrieved from https://www.erowid.org/chemicals/2cd/2cd_smartpills1.shtml</ref>


Many who have experimented with this substance report that it is calmer, easier to handle and more comfortable on the body than other closely related [[psychedelic]] [[phenethylamine]]s. While not especially visual or physically euphoric, it is said to be very lucid in its head-space, analytical and cognitively unimpairing.
Today, 2C-D is used both recreationally and as an [[entheogen]]. It is rarely sold on the streets and almost exclusively distributed as a gray area [[research chemical]] by online vendors.  
 
Today, 2C-D is used both recreationally and as an [[entheogenic]] substance. It is rarely sold on the streets and almost exclusively distributed as a gray area [[research chemical]] through online vendors.  


==History and culture==
==History and culture==
{{historyStub}}
The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences,<ref>Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084</ref>, but initial trials by [[Alexander Shulgin]] at sub-threshold doses were carried out in 1964. Further investigations at higher doses were carried out by Shulgin and his fellow researchers between 1974 and 1978.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf</ref> The name '2C-D' derives from the chemical's structure - it is the 2-Carbon analogue of [[DOM]].
The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences,<ref>Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084</ref>, but initial trials by [[Alexander Shulgin]] at sub-threshold doses were carried out in 1964. Further investigations at higher doses were carried out by Shulgin and his fellow researchers between 1974 and 1978.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf</ref> The name '2C-D' derives from the chemical's structure - it is the 2-Carbon analogue of [[DOM]].


Notably, Shulgin referred to 2C-D as a “pharmacological tofu,” meaning it can extend or potentiate the effect of other substances without coloring the experience too much, in a manner similar to how tofu absorbs the flavors of sauces or spices it is cooked with.{{citation needed}} While some people have claimed 2C-D is relatively uninteresting as a psychedelic on its own many users have come to strongly disagree with this early assessment and believe that 2C-D is an extremely versatile and fully-fledged synthetic [[entheogen]] in its own right.
Notably, Shulgin referred to 2C-D as a “pharmacological tofu,” meaning it can extend or potentiate the effect of other substances without overly coloring the experience, in a manner similar to how tofu absorbs the flavors of sauces or spices it is cooked with.{{citation needed}} While some use this as evidence that 2C-D is relatively uninteresting as a psychedelic on its own, others strongly disagree with this assessment and hold that 2C-D is an unusually versatile and fully-fledged [[psychedelic]] in its own right.  


Albeit showing promise as a very functional psychostimulant<ref>Zuba, D., & Sekula, K. (2013). Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Testing and Analysis, 5(8), 634–645. https://doi.org/10.1002/dta.1397</ref><ref>King, L. A. (2014). New phenethylamines in Europe. Drug Testing and Analysis, 6(7–8), 808–818. https://doi.org/10.1002/dta.1570</ref> with very successful studies investigating the use in psychotherapy in Germany,<ref>Schneider, U. (2004). Aspekte des Psychischen: Festschrift anlässlich des 60. Geburtstags von Hinderk M. Emrich. Würzbug, Germany: Königshausen & Neumann. '''No complete fulltext was available at the time of writing, please refer to the Google Scholar document: https://books.google.de/books?id=yo45tYQj2-MC&lpg=PA129&ots=tW1EqmhrGF&dq=DMM-PEA&hl=de&pg=PA129&output=embed.'''</ref> 2C-D has not found widespread use. This has been argued to be due to the previously limited diversity of substances on the market - a consumer dynamic which has changed significantly with the advent of the internet - allowing a broader freedom of choice for explorers of psychedelic phenethylamines.<ref>Martin, J. (2014). Drugs on the Dark Net. London: Palgrave Macmillan UK. https://doi.org/10.1057/9781137399052</ref> Of these, it tends to be substantially harder to find and notably more expensive by weight.{{citation needed}}
Despite showing promise as a very functional psychostimulant<ref>Zuba, D., & Sekula, K. (2013). Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Testing and Analysis, 5(8), 634–645. https://doi.org/10.1002/dta.1397</ref><ref>King, L. A. (2014). New phenethylamines in Europe. Drug Testing and Analysis, 6(7–8), 808–818. https://doi.org/10.1002/dta.1570</ref> with successful studies investigating the use in psychotherapy in Germany,<ref>Schneider, U. (2004). Aspekte des Psychischen: Festschrift anlässlich des 60. Geburtstags von Hinderk M. Emrich. Würzbug, Germany: Königshausen & Neumann. '''No complete fulltext was available at the time of writing, please refer to the Google Scholar document: https://books.google.de/books?id=yo45tYQj2-MC&lpg=PA129&ots=tW1EqmhrGF&dq=DMM-PEA&hl=de&pg=PA129&output=embed.'''</ref> 2C-D has not found widespread use. This has been argued to be due to the previously limited diversity of substances on the market - a consumer dynamic which has changed significantly with the advent of the internet - allowing a broader freedom of choice for explorers of psychedelic phenethylamines.<ref>Martin, J. (2014). Drugs on the Dark Net. London: Palgrave Macmillan UK. https://doi.org/10.1057/9781137399052</ref> Of these, it tends to be substantially harder to find and notably more expensive by weight.{{citation needed}}
==Chemistry==
==Chemistry==
[[File:Phenethylamine.png|thumb|right|253px|thumb|right|253px||Generic structure of a phenethylamine molecule]]
[[File:Phenethylamine.png|thumb|right|253px|thumb|right|253px||Generic structure of a phenethylamine molecule]]
Line 34: Line 35:


|{{effects/physical|
|{{effects/physical|
*'''[[Effect::Stimulation]]''' & '''[[Effect::Sedation]]''' - In terms of its effects on the physical energy levels of the user, the 2C-D experience begins with mild sedation that increases as the trip progresses, and lacks the distinctive energetic feeling associated with most [[phenethylamines]].
*'''[[Effect::Stimulation]]''' - In terms of its effects on the physical energy levels of the user, the 2C-D experience begins with mild sedation that gives way to moderate stimulation as the experience progresses. It lacks the forceful energetic push associated with most psychedelic [[phenethylamines]].
*'''[[Effect::Spontaneous physical sensations]]''' -  The "body high" of 2C-D can be described as a pleasurable, all-encompassing comfort sensation. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
*'''[[Effect::Spontaneous physical sensations]]''' -  The "body high" of 2C-D can be described as a pleasurable, all-encompassing comfort sensation. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
*'''[[Effect::Bodily control enhancement]]''' - Whilst at lower doses one may find that their bodily control is enhanced, at higher dosages it seems to become suppressed.
*'''[[Effect::Bodily control enhancement]]''' - Whilst at lower doses one may find that their bodily control is enhanced, at higher dosages it seems to become suppressed.
Line 40: Line 41:
*'''[[Effect::Temperature regulation suppression]]'''
*'''[[Effect::Temperature regulation suppression]]'''
*'''[[Effect::Increased heart rate]]'''
*'''[[Effect::Increased heart rate]]'''
*'''[[Effect::Nausea]]''' -  Although nausea remains present, in comparison to other [[phenethylamines]] such as [[2C-E]], [[2C-I]] or [[2C-B]], this remains extremely mild and dissipates quickly even with higher dosages.
*'''[[Effect::Dehydration]]'''
*'''[[Effect::Dehydration]]'''
*'''[[Effect::Nausea]]''' -  In comparison to other [[phenethylamines]] such as [[2C-E]], [[2C-I]] or [[2C-B]], any nausea produced by this substance tends to be very mild and dissipates quickly even with higher dosages.
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Pupil dilation]]'''


}}
}}
{{effects/visual|
{{effects/visual|
Compared to other members of the 2C-x family like [[2C-B]], the visual effects of 2C-D have been noted for being understated until heavier doses are reached. After this point, a full spectrum of hallucinatory visual phenomena begin to appear. 
====Enhancements====
====Enhancements====
*'''[[Effect::Colour enhancement]]'''
*'''[[Effect::Colour enhancement]]'''
*'''[[Effect::Pattern recognition enhancement]]'''
*'''[[Effect::Pattern recognition enhancement]]'''
*'''[[Effect::Visual acuity enhancement|Acuity enhancement]]'''
*'''[[Effect::Visual acuity enhancement]]'''


====Distortions====
====Distortions====
*'''[[Effect::Drifting]]''' ''([[Drifting#Melting|melting]], [[Drifting#Flowing|flowing]], [[Drifting#Breathing|breathing]] and [[Drifting#morphing|morphing]])'' - In comparison to other psychedelics, this effect can be described as low in detail, slow and smooth in motion, static in appearance and realistic in style.
*'''[[Effect::Drifting]]''' ''([[Drifting#Melting|melting]], [[Drifting#Flowing|flowing]], [[Drifting#Breathing|breathing]] and [[Drifting#morphing|morphing]])'' - In comparison to other psychedelics, this effect can be described as low in detail, slow and smooth in motion, static in appearance and realistic in style.
*'''[[Effect::Tracers]]'''
*'''[[Effect::Tracers]]'''
*'''[[Effect::After images]]'''
*'''[[Effect::Colour shifting]]'''
*'''[[Effect::Colour shifting]]'''
*'''[[Effect::Colour tinting]]'''
*'''[[Effect::Symmetrical texture repetition]]'''
*'''[[Effect::Recursion]]'''
*'''[[Effect::Diffraction]]'''


====[[effect::Geometry]]====
====[[effect::Geometry]]====
The visual geometry able to be produced by this substance can be described as more similar in appearance to that of [[DOM]] or [[25D-NBOMe]] than that of [[LSD]], [[2C-B]] or [[2C-I]]. It can be comprehensively described as structured in its organization, organic in style, intricate in complexity, large in style, slow and smooth in motion, colorful in scheme, bright in color, blurred in its edges and equally rounded and angular in its corners. It gives off a natural feel at higher dosages. While the final level of 2C-D geometry has yet to be formally confirmed, it seems more likely that it would result in states of [[Effect::8B Geometry|level 8B]] visual geometry over [[8A Geometry|level 8A]].
The visual geometry that is able to be produced by this substance can be described as more similar in appearance to that of [[DOM]] or [[25D-NBOMe]] than that of [[LSD]], [[2C-B]] or [[2C-I]]. It can be comprehensively described as structured in its organization, organic in style, intricate in complexity, large in style, slow and smooth in motion, colorful in scheme, bright in color, blurred in its edges and equally rounded and angular in its corners. It gives off a natural feel at higher dosages. While the final level of 2C-D geometry has yet to be formally confirmed, it seems more likely that it would result in states of [[Effect::8B Geometry|level 8B]] visual geometry over [[8A Geometry|level 8A]].


====Hallucinatory states====
====Hallucinatory states====
Line 66: Line 73:
}}
}}
|{{effects/cognitive|
|{{effects/cognitive|
The head space of 2C-D is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high doses. The feeling of "unaltered consciousness" may be bothersome to trippers who want an intense experience because the head space is fairly normal, stable and therefore typically considered rather uninteresting to those new to hallucinogenic experiences.
The head space of 2C-D is described by many as being lucid, insightful and relatively normal in its thought processes even at moderate to high doses. The feeling of unaltered consciousness may be unsatisfying to users who want an intense experience because the head space is fairly normal, stable and therefore sometimes uninteresting to those who are new to hallucinogenic experiences.
*'''[[Effect::Analysis enhancement]]'''
*'''[[Effect::Analysis enhancement]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Conceptual thinking]]'''

Revision as of 14:27, 12 July 2017

Summary sheet: 2C-D
2C-D
Chemical Nomenclature
Common names 2C-D, 2C-M, LE-25
Substitutive name 2,5-Dimethoxy-4-methylphenethylamine
Systematic name 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminoethane
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 3 mg
Light 10 - 25 mg
Common 25 - 50 mg
Strong 50 - 100 mg
Heavy 100 mg +
Duration
Total 3 - 5 hours
Onset 15 - 45 minutes
Come up 20 - 40 minutes
Peak 1.5 - 2.5 hours
Offset 0.5 - 1.5 hours
After effects 1 - 4 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions


2,5-Dimethoxy-4-methylphenethylamine (also known as 2C-M and more commonly as 2C-D) is a synthetic psychedelic of the phenethylamine chemical class that produces short-lived psychedelic effects when administered. Its sensory and cognitive effects profile has been described as being the most similar to that of mescaline among members of the 2C-x family, albeit with a notably shorter duration.

The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences.[1] Initial trials by Alexander Shulgin at sub-threshold doses in humans were carried out in 1964.[2]

In his book PiHKAL ("Phenethylamines I Have Known And Loved"), Shulgin lists the dosage range as being from 20 to 60 mg. This is now regarded by some as a conservative estimate as it has since been reported that substantially higher doses are capable of inducing a full spectrum of classical psychedelic effects while remaining physically unthreatening, a relatively unique quality in the 2C-x family.

Many anecdotal reports suggest that it is calmer, easier to handle and more comfortable on the body than other closely related psychedelic phenethylamines. While not especially visual or physically euphoric, it is said to be very lucid in its head-space, analytical and cognitively unimpaired.

Lower doses of 2C-D (generally 10 mg or less) have been explored for its use as a potential nootropic, albeit with mixed results.[3]

Today, 2C-D is used both recreationally and as an entheogen. It is rarely sold on the streets and almost exclusively distributed as a gray area research chemical by online vendors.

History and culture

The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences,[4], but initial trials by Alexander Shulgin at sub-threshold doses were carried out in 1964. Further investigations at higher doses were carried out by Shulgin and his fellow researchers between 1974 and 1978.[5] The name '2C-D' derives from the chemical's structure - it is the 2-Carbon analogue of DOM.

Notably, Shulgin referred to 2C-D as a “pharmacological tofu,” meaning it can extend or potentiate the effect of other substances without overly coloring the experience, in a manner similar to how tofu absorbs the flavors of sauces or spices it is cooked with.[citation needed] While some use this as evidence that 2C-D is relatively uninteresting as a psychedelic on its own, others strongly disagree with this assessment and hold that 2C-D is an unusually versatile and fully-fledged psychedelic in its own right.

Despite showing promise as a very functional psychostimulant[6][7] with successful studies investigating the use in psychotherapy in Germany,[8] 2C-D has not found widespread use. This has been argued to be due to the previously limited diversity of substances on the market - a consumer dynamic which has changed significantly with the advent of the internet - allowing a broader freedom of choice for explorers of psychedelic phenethylamines.[9] Of these, it tends to be substantially harder to find and notably more expensive by weight.[citation needed]

Chemistry

Generic structure of a phenethylamine molecule

2C-D, or 2,5-dimethoxy-4-methylphenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. 2C-D contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as a methyl group attached to carbon R4 of the phenyl ring.

2C-D belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.

Pharmacology

Further information: Serotonergic psychedelic

2C-D's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 2C-D use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-D is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried 2C-D suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

2C-D is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 2C-D is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 2C-D presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 2C-D all psychedelics will have a reduced effect.

Dangerous interactions

This dangerous interactions section is a stub.

As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.

Although many substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be relatively harmless in low doses of each but can still increase the risk of unpredictable injury or death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Legality

  • Australia: Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.[11]
  • Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[12]
  • Canada: 2C-D would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[13]
  • China - As of October 2015 2C-D is a controlled substance in China.[14]
  • Denmark: 2C-D is added to the list of Schedule B controlled substances.[15]
  • Germany: On December 13, 2014, 2C-D was added to the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.[16]
  • Japan: 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.[17]
  • Latvia: 2C-D is a Schedule I controlled substance.[18]
  • Switzerland: Possession, production and sale is illegal.[19]
  • Sweden: 2C-D is classified as a health hazard as of March 1, 2005, in the regulation SFS 2005:26, making it illegal to sell or possess.[20]
  • United Kingdom: 2C-D is a Class A controlled substance as it is covered by the phenethylamine derivatives clause of the Misuse of Drugs Act of 1971.[citation needed]
  • United States: 2C-D is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.[21]

See also

References

  1. Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084
  2. Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf
  3. Lemaire, D. (1990). Erowid 2C-D Vault: Smart Pills, by Hosten & Lazar. Retrieved from https://www.erowid.org/chemicals/2cd/2cd_smartpills1.shtml
  4. Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084
  5. Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf
  6. Zuba, D., & Sekula, K. (2013). Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Testing and Analysis, 5(8), 634–645. https://doi.org/10.1002/dta.1397
  7. King, L. A. (2014). New phenethylamines in Europe. Drug Testing and Analysis, 6(7–8), 808–818. https://doi.org/10.1002/dta.1570
  8. Schneider, U. (2004). Aspekte des Psychischen: Festschrift anlässlich des 60. Geburtstags von Hinderk M. Emrich. Würzbug, Germany: Königshausen & Neumann. No complete fulltext was available at the time of writing, please refer to the Google Scholar document: https://books.google.de/books?id=yo45tYQj2-MC&lpg=PA129&ots=tW1EqmhrGF&dq=DMM-PEA&hl=de&pg=PA129&output=embed.
  9. Martin, J. (2014). Drugs on the Dark Net. London: Palgrave Macmillan UK. https://doi.org/10.1057/9781137399052
  10. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  11. New Psychoactive Substances (National Drug and Alcohol Research Centre 2014) | https://comorbidity.edu.au/sites/default/files/cre/page/New%20Psychoactive%20Substances.pdf
  12. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  13. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
  14. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015. 
  15. Bekendtgørelse om euforiserende stoffer | https://www.retsinformation.dk/Forms/R0710.aspx?id=137169
  16. Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften (28. BtMÄndV)| http://www.buzer.de/gesetz/11392/a189949.htm
  17. Analytical Data of Designated Substances (Shitei-Yakubutsu) Controlled by the Pharmaceutical AŠairs Law in Japan, Part I: GC-MS and LC-MS | https://www.erowid.org/references/texts/show/7395docid7635
  18. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  19. http://web.archive.org/web/20170329020935/https://www.admin.ch/opc/de/classified-compilation/20101220/index.html
  20. Svensk författningssamling | http://www.notisum.se/rnp/sls/sfs/20050026.pdf
  21. S. 3187: Food and Drug Administration Safety and Innovation Act, Subtitle D-Synthetic Drugs | http://www.govtrack.us/congress/bills/112/s3187/text